Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods and compositions for diagnosing or detecting lung cancers

一种组合物、肺癌的技术，应用在组合化学、生物化学设备和方法、生物信息学等方向，能够解决难以准确地预测、不适当调控等问题

Inactive Publication Date: 2018-02-16
THE WISTAR INST OF ANATOMY & BIOLOGY
View PDF11 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

It has been noted that the complex regulatory network of interactions between miRNAs and target genes makes it difficult to accurately predict which genes will actually be inappropriately regulated in response to a given miRNA

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for diagnosing or detecting lung cancers
  • Methods and compositions for diagnosing or detecting lung cancers
  • Methods and compositions for diagnosing or detecting lung cancers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0172] Example 1: Sample size calculation

[0173] The calculation is based on figure 1 PAXgene data as described in. We used data from the current PAXgene dataset of 23 cancer patients and 25 controls to design the sample size needed to achieve the desired 90% accuracy on the test set. We randomly selected training sets of different sizes with 24 to 44 samples, which is equivalent to 50% to 90% of all samples. The sample size is gradually increased in increments of 2 to allow one cancer sample and one control sample to be added at each step. For each given sample size, 50 resamples are performed.

[0174] Then a t-test was performed on each training set to identify the top 100 genes ranked by p value. The gene list is further reduced by removing any low expressors (expression not exceeding twice the average background level of all samples in the cancer and non-cancer groups).

[0175] The remaining 58 genes are then used to aggregate all samples, including those originally kept ...

Embodiment 2

[0177] Example 2-RNA purification and quality assessment

[0178] RNA purification for gene and miRNA array processing is performed using standard procedures such as the regular services of Genomics Core. Use of Qiagen that allows simultaneous purification of mRNA and miRNA TM The standard commercially available kit for the preparation of PAXgene RNA. The resulting RNA is used for mRNA or miRNA profile analysis.

[0179] RNA quality is measured using a biological analyzer. Use only RNA integrity value> 7.5 sample. A constant amount (100ng) of total RNA was amplified (aRNA) using an Illumina-approved RNA amplification kit (Epicenter). This program provides sufficient amplification material for multiple repeated gene and miRNA expression. If an alternative collection system will be used to collect smaller samples at a later date, RNA quantities as low as 10 ng can be used.

Embodiment 3

[0180] Example 3-Data preprocessing, array quality control, detection filtering

[0181] Array data is processed by Illumina’s Bead Studio, and the expression levels of signals and control probes are derived for analysis. In order to reduce experimental noise, the data was filtered by removing non-informative probes (probes that were not detected in more than 95% of all samples) and probes that did not vary by at least 1.2 times between any two samples. Then normalize the expression level quantile. These programs produce quantile-normalized data, and non-informative probe data is removed.

[0182] After each hybridization batch, we use all signal probes (> The expression level of 40,000) was calculated as the gene-wise global correlation as the median Spearman correlation on all microarrays, and the median absolute deviation of the global correlation was calculated. For each microarray, the median Spearman correlation is calculated relative to all other arrays, and arrays whose m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A multi-analyte composition for the diagnosis of lung cancer or lung disease comprises a ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an mRNA gene transcript from a mammalian blood sample, and an additional ligand selected from a nucleic acid sequence, polynucleotide or oligonucleotide capable of specifically complexing with, hybridizing to, or identifying an miRNA of a gene from a mammalian blood sample. Each ligand and additional ligand binds to a different gene transcript or miRNA andthe gene transcripts and miRNA identified form a characteristic profile of a stage of lung cancer or lung disease. Methods of using this composition for diagnosis and evaluation and methods for developing such compositions are described.

Description

[0001] Materials submitted in electronic form are incorporated by reference [0002] The applicant hereby incorporates by reference the sequence listing materials submitted with this article in electronic form. The file is labeled "WST155PCT_ST25.txt", was created on May 19, 2016, and is 43KB. [0003] Government Rights Statement [0004] The present invention was completed with government support under the grant number P30CA010815 granted by the National Institutes of Health. The government has certain rights in this invention. Background of the invention [0005] Lung cancer is the most common cause of cancer death worldwide, with approximately 220,000 newly diagnosed cases each year, or approximately 13% of all cancer diagnoses. More than 27% of all cancer deaths are due to lung cancer, and about 150,000 people die every year. The current diagnosis rate is advanced, that is, more than 70% of diagnoses are stage III and above, and only 15% of such lung cancers are diagnosed in an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C40B30/04G16B25/10G16B40/20
CPCC12Q2600/158C12Q2600/178G16B25/00G16B40/00C12Q1/6886G16B40/20G16B25/10G16H50/70C12Q2600/106C12Q2600/112C12Q2600/118
Inventor L·C·肖维M·K·肖维A·V·科森科夫
Owner THE WISTAR INST OF ANATOMY & BIOLOGY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com